Notice of Annual general meeting in Swedish Orphan Biovitrum AB (publ) The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting…
FDA approves once-weekly efanesoctocog alfa, a new class of high-sustained factor VIII therapy for haemophilia A: Swedish Orphan Biovitrum AB STOCKHOLM, Feb. 24, 2023 /PRNewswire/ -- Sobi® today announced that the US Food and Drug Administration (FDA) has approved efanesoctocog…
Sobi publishes Q4 and FY 2022 report: a good year and a solid future STOCKHOLM, Feb. 8, 2023 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter…
Sobi publishes Q4 and FY 2022 report: a good year and a solid future Swedish Orphan Biovitrum AB (publ) (http://www.sobi.com/) (Sobi®) today announced its report for the fourth quarter and full year of 2022 Fourth quarter…